Key Drivers
- Steady margins
- Thin free cash flow
- Moderate leverage
AIAI Summary
STVN's story has improved from a steady medtech name to a higher-value drug-delivery platform, but the investment case now hinges on whether Deora and High-Value Solutions can convert solid revenue growth into durable free cash flow as heavy capex and a demanding valuation leave little room for execution missteps.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Steady margins
- •Thin free cash flow
- •Moderate leverage
STVN delivers steady but only modest profitability with solid operating cash flow, but thin free cash flow, manageable leverage, and a demanding valuation make the risk/reward look limited.
Price Behavior
Key Price Behavior Insights:
- •Trend recovery
- •Support retest
- •Volatility risk
STVN has turned modestly positive over the last month, rebounding from a mid-June low and now needing to hold $18.39-$18.46 to keep momentum intact.
Fast, uneven rebound after a sharp mid-June selloff suggests near-term profit-taking risk
Sentiment & News
Key News Insights:
- •Deora launch
- •HVS expansion
- •Engineering delays
STVN is showing stronger growth through Deora™ and GLP-1-driven demand, with High-Value Solutions expanding while Engineering faces only temporary timing-related softness.
This mix should support Stevanato's near-term outlook by strengthening higher-margin drug-delivery demand even as project timing temporarily weighs on Engineering
Similar Companies in Healthcare
Other companies in the same sector with AI ratings